Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nigella Sativa  COVID-19 treatment studies for Nigella Sativa  C19 studies: Nigella Sativa  Nigella Sativa   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -8% Improvement Relative Risk Oxygen time 27% Hospitalization time 29% c19early.org/ns Setayesh et al. IRCT20200330046899N1 Nigella Sativa RCT LATE Is late treatment with nigella sativa+combined treatments beneficial for COVID-19? RCT 79 patients in Iran (June - September 2020) Lower need for oxygen therapy (p=0.007) and shorter hospitalization (p<0.0001) Setayesh et al., Integrative Medicine Research, doi:10.1016/j.imr.2022.100869 Favors nigella sativa Favors control
Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): a randomized clinical trial
Setayesh et al., Integrative Medicine Research, doi:10.1016/j.imr.2022.100869, IRCT20200330046899N1
Setayesh et al., Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): a randomized clinical.., Integrative Medicine Research, doi:10.1016/j.imr.2022.100869, IRCT20200330046899N1
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT 41 patients treated with nigella sativa, glycyrrhiza glabra, punica granatum, and rheum palmatum, and 41 control patients, showing shorter hospitalization with treatment.
risk of death, 7.9% higher, RR 1.08, p = 1.00, treatment 1 of 38 (2.6%), control 1 of 41 (2.4%).
oxygen time, 26.8% lower, relative time 0.73, p = 0.007, treatment mean 3.0 (±1.6) n=38, control mean 4.1 (±1.9) n=41.
hospitalization time, 28.7% lower, relative time 0.71, p < 0.001, treatment mean 5.7 (±1.9) n=38, control mean 8.0 (±1.8) n=41.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Setayesh et al., 3 Jun 2022, Randomized Controlled Trial, Iran, peer-reviewed, mean age 59.1, 7 authors, study period June 2020 - September 2020, this trial uses multiple treatments in the treatment arm (combined with glycyrrhiza glabra, punica granatum, and rheum palmatum) - results of individual treatments may vary, trial IRCT20200330046899N1.
Contact: hasheminasab@zaums.ac.ir, hashemifa67@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperNigella SativaAll
Abstract: Integrative Medicine Research 11 (2022) 100869 Contents lists available at ScienceDirect Integrative Medicine Research journal homepage: www.elsevier.com/locate/imr Original Article Efficacy of a Persian herbal medicine compound on coronavirus disease 2019 (COVID-19): A randomized clinical trial Mohammad Setayesh a, Mehrdad Karimi b, Arman Zargaran c, Hamid Abousaidi d, Armita Shahesmaeili e, Fatemeh Amiri f, Fatemeh Sadat Hasheminasab g,∗ a Department of Traditional Medicine, School of Persian medicine, Kerman University of Medical Sciences, Kerman, Iran Department of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran Department of Traditional Pharmacy, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran d Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran e HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health Kerman University of Medical Sciences, Kerman, Iran f Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran g Pharmacology Research Center, Zahedan University of Medical Sciences, Zahedan, Iran b c a r t i c l e i n f o Article history: Received 31 December 2021 Revised 27 May 2022 Accepted 30 May 2022 Available online 3 June 2022 Keywords: Glycyrrhiza glabra Nigella sativa Rheum palmatum COVID-19 Persian medicine herbal medicine a b s t r a c t Background: The global attention to the capacities of traditional medicine for alleviating the clinical manifestations of COVID-19 has been growing. The present trial aimed to evaluate the efficacy and safety of a Persian herbal medicine formula among patients with COVID-19. Methods: The present trial was conducted in Afzalipour hospital, Kerman, Iran, from June to September 2020. Hospitalized COVID-19 patients were randomly divided into intervention (Persian herbal medicine formula + routine treatment) or control (only routine treatment) groups. The intervention group received both capsule number 1 and 2 every 8 hours for 7 days. Capsule number 1 contained extract of the Glycyrrhiza glabra, Punica granatum, and Rheum palmatum, and the second capsule was filled by Nigella sativa powder. Participants were followed up to 7 days. The primary outcome was the number of hospitalization days, while cough, fever, and respiratory rate, days on oxygen (O2 ) therapy, and mortality rate were considered as the secondary outcomes. Results: Eighty-two patients were enrolled to the study, while 79 cases completed the trial and their data were analyzed (mean age: 59.1 ± 17.1 years). Based on the results, the Persian medicine formula decreased the mean hospitalization days, so that the mean difference of length of hospitalization as primary outcome was 2.95 ± 0.43 days. A significant clinical improvement was observed regarding dyspnea, need for O2 ) therapy, and respiratory rate in the intervention group. No adverse effects were reported. Conclusion: The present study supported the use of the Persian medicine formula as an adjuvant therapy for hospitalized COVID-19 patients. Study registration: Iranian Registry of Clinical Trials (www.irct.ir): IRCT2020 0330 046899N1. Study registration: Iranian Registry of Clinical Trials (www.irct.ir): IRCT2020 0330 046899N1. © 2022 Korea Institute of Oriental Medicine. Published by Elsevier B.V. This is an open access article under the CC..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit